mycophenolate mofetil (CellCept)

Phase 3

Roche Holding AG (RHHBY)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Myasthenia Gravis, Generalized

View Full Landscape

Drug Information

Target Indication

Myasthenia Gravis, Generalized

Clinical Trial

NCT00683969

Last updated: 2/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA2/14/1996

CellCept

CellCept is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in adult and paediatric (1 to 18 years of age) patients receiving allogeneic renal, cardiac or hepatic transplants.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

RHHBY

Roche Holding AG

Biotechnology•Europe•NYSE

Related Pipeline

RO7204239Phase 3

Obesity

Vemurafenib in combination with cobimetinibPhase 3

Haematological Malignancy

MabTheraPhase 3

Humoral Rejection in Kidney Transplantation

RO7239361Phase 3

Duchenne Muscular Dystrophy

trastuzumab (Herceptin®)Phase 3

Breast Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts